20th International AIDS Conference - Melbourne, Australia


TUAB01 Antiretroviral Therapy: Not All Strategies Are Created Equal
  Oral Abstract Session : Track B
Venue: Plenary 2
Time: 22.07.2014, 11:00 - 12:30
Co-Chairs: Joel Gallant, United States
Adeeba Kamarulzaman, Malaysia

11:00
TUAB0101
Abstract
Powerpoint
Webcast
Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095)
H.-J. Stellbrink1, P. Pulik2, J. Szlavik3, D. Murphy4, A. Lazzarin5, J. Portilla6, A. Rinehart7, E. Le Fevre8, A. Fang9, S. Valluri9, G. Mukwaya10, J. Heera11
1ICH-Study Center, Hamburg, Germany, 2SPZOZ Wojewodzki Szpital Zakazny, Warsaw, Poland, 3Egyesittet Szent Istvan es Szent Laszio Korhaz-Rendelointezet, Budapest, Hungary, 4Clinique Medicale L'Actuel, Montreal, Canada, 5Ospedale San Raffaele, Divisione di Malattie Infettive, Milan, Italy, 6Hospital General Universitario de Alicante, Unidad de VIH, Alicante, Spain, 7ViiV Healthcare, Research Triangle Park, United States, 8ViiV Healthcare, Brentford, United Kingdom, 9Pfizer Inc., New York, United States, 10Pfizer Inc., Medicines Development Group, New York, United States, 11Pfizer Inc., Groton, United States

11:15
TUAB0102
Abstract
Powerpoint
Webcast
Effect of viral suppression below 20 copies of HIV-RNA per millilitre of plasma on virological outcome of treated HIV-infected patients
R. Teira1, P. Muñoz-Sanchez2, I. Suarez-Lozano3, E. Martinez4, A. Muñoz-Sanz5, B. de la Fuente6, M. Montero7, J. Borrallo8, T. Puig9, F. Vidal10, M. Castaño11, V. Estrada12, P. Geijo13, B. Roca14, T. Sánchez15, A. Terrón16, E. Deig17, E. Pedrol18, E. Ribera19, P. Viciana20, P. Domingo21, F. Lozano22, M.J. Galindo23, M. Garrido24, VACH Study Group
1Hospital de Sierrallana, Torrelavega, Spain, 2Hospital de Basurto, Bilbao, Spain, 3Hospital Infanta Elena, Huelva, Spain, 4Hospital de Albacete, Albacete, Spain, 5Hospital Infanta Cristina, Badajoz, Spain, 6Hospital de Cabueñes, Gijón, Spain, 7Hospital La Fe, Valencia, Spain, 8Hospital Clínico, Puerto Real, Spain, 9Hospital Arnau de Vilanova, Lleida, Spain, 10Hospital Joan XXIII, Tarragona, Spain, 11Hospital Carlos Haya, Malaga, Spain, 12Hospital Clínico de San Carlos, Madrid, Spain, 13Hospital Virgen de la Luz, Cuenca, Spain, 14Hospital General, Castellón, Spain, 15Hospital Virgen del Rosell, Cartagena, Spain, 16Hospital del SAS, Jerez de la Frontera, Spain, 17Hospital General, Granollers, Spain, 18Xarxa Sanitaria i Social Santa Tecla, Tarragona, Spain, 19Hospital Vall d´Hebrón, Barcelona, Spain, 20Hospital Virgen del Rocío, Sevilla, Spain, 21Hospital Santa Creu i Sant Pau, Barcelona, Spain, 22Hospital de Valme, Sevilla, Spain, 23Hospital Clínico, Valencia, Spain, 24VACH Study Group Data Management, Huelva, Spain

11:30
TUAB0103
Abstract
Powerpoint
Webcast
Switching from first antiretroviral therapy regimen while virologically suppressed is associated with increased risk of subsequent virologic failure
M. Hull1,2, A. Cescon1, J. Raboud3,4, M.B. Klein5, S. Walmsley3,4, E. Ding1, S. Shurgold1, C. Tsoukas5, J.S. Montaner1,2, N. Machouf6, M.R. Loutfy4,7, C. Cooper8, A.N. Burchell4,9, R.S. Hogg1,10, CANOC Collaboration
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada, 2University of British Columbia, Vancouver, Canada, 3University Health Network, Toronto, Canada, 4University of Toronto, Toronto, Canada, 5McGill University, Montreal, Canada, 6Clinique Médicale l'Actuel, Montreal, Canada, 7Women's College Research Institute, Toronto, Canada, 8The Ottawa Hospital, Division of Infectious Diseases, Ottawa, Canada, 9Ontario HIV Treatment Network, Toronto, Canada, 10Simon Fraser University, Burnaby, Canada

11:45
TUAB0104
Abstract
Powerpoint
Webcast
DTG-containing regimens are active in INI-naïve patients with a history of NRTI resistance
J. Demarest1, M. Underwood2, M. St Clair2, D. Dorey3, S. Almond3, R. Cuffe4, D. Brown5, G. Nichols6
1ViiV Healthcare, Global R&D, Research Triangle Park, United States, 2GlaxoSmithKline, Clinical Virology, Research Triangle Park, United States, 3GlaxoSmithKline, Clinical Statistics, Mississauga, Canada, 4ViiV Healthcare, Statistics, London, United Kingdom, 5ViiV Healthcare, Medical Affairs, Abbotsford, Australia, 6GlaxoSmithKline, Infectious Disease R&D, Research Triangle Park, United States

12:00
TUAB0105LB
Abstract
Powerpoint
Webcast
Baseline resistance, virological failure and emergent resistance in the SECOND-LINE randomised trial
M. Boyd1, C. Moore1, J.-M. Molina2, R. Wood3, J.S. Madero4, M. Wolff5, K. Ruxrungtham6, M. Losso7, B. Renjifo8, H. Teppler9, A. Kelleher1, J. Amin1, S. Emery1, D. Cooper1, SECOND-LINE Study Group
1UNSW Australia, The Kirby Institute for Infection and Immunity in Society, Sydney, Australia, 2Hospital Saint-Louis, Department of Clinical Infectious Diseases, Paris, France, 3University of Cape Town, Desmond Tutu HIV Foundation, Cape Town, South Africa, 4Instituto Nacional de Ciencias Medicas y Nutricion 'Salvador Zubirán', Department of Clinical Infectious Diseases, Mexico D.F., Mexico, 5Hospital San Borja-Arriaran, University of Chile, Santiago, Chile, 6Chulalongkorn University, The HIV Netherlands Australia Thailand AIDS Research Collaboration, Bangkok, Thailand, 7Hospital J. M. Ramos Mejía, Servicio de Immunocompromatidos, Buenos Aires, Argentina, 8AbbVie Inc., Global Medical Affairs, Fort Lauderdale, United States, 9Merck Sharpe & Dohme Inc, Merck Clinical Research - Infectious Diseases, Whitehouse Station, United States

12:15
TUAB0106
Webcast
Moderated discussion

Powerpoints presentations
Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095) - Eric Le Fevre

Effect of viral suppression below 20 copies of HIV-RNA per millilitre of plasma on virological outcome of treated HIV-infected patients - Ramon Teira

Switching from first antiretroviral therapy regimen while virologically suppressed is associated with increased risk of subsequent virologic failure - Marina Klein

DTG-containing regimens are active in INI-naïve patients with a history of NRTI resistance - James Demarest

Baseline resistance, virological failure and emergent resistance in the SECOND-LINE randomised trial - Mark Boyd



Rapporteur report

Track B report by Silvia Nozza


This session presented not conventional triple antiretroviral therapy in naive patients, use of ultrasensitive viral load and resistance in clinical practice.

 

Eric Le Fevre presented the results of MODERN trial. This is a Phase 3, randomized, double blind trial that compared triple therapy (TDF/FTC+DRV800/RTV100 mg) versus dual therapy (Maraviroc 150 mg QD+DRV800/RTV100 mg) in HIV positive patients naive to antiretroviral therapy. 804 were randomised to receive TDF/FTC (N=402) or MVC 150 mg QD (N=402). Primary endpoint was proportion of subjects with VL<50 copies/mL at week 48. At primary analysis 77.3% in MVC arm 86.8% in TDF/FTC reached the end-point. In evaluable patients no emergence of resistance and CXCR4 tropic virus were observed. In MVC arm there was a worse response. Response was worse in patients with  high viral load (HIVRNA>100.000 copies/mL)  low baseline CD4 count (200-350 cells/mmc) at baseline.

 

Ramon Teira evaluated patients with HIVRNA 20-50 copies/mL in a Spanish cohort starting triple antiretroviral therapy. Virological failure was defined as viral load>200 copies/mL. Study included 21480 subjects starting ART, 38.6% achieving VL<50 copies/mL, 39.1% VL<20 copies/mL: among those who achieved viral load below 20 copies/mL virological failure was not higher in patients who had transient blips to 20-50 copies/mL.

 

Marina Klein presented CANOC cohort data about switch of antiretroviral therapy from first regimen. Outcomes were factors associated to switch and risk of virological failure. 2807 were included, 1804 never switched, 391 switched regime once, 612 > 2 times. Switching occured after 0.8 year.  More switchs occured in IVDU and females. Switching was associated with subsequent virological failure defined as virological rebound.

 

Jim Demarest presented a sub-analysis on resistance of the SAILING study. He evaluated 354 patients treated with background therapy plus dolutegravir 50 mg QD and 361 with raltegravir. 21/354 (6%) in DTG failed, 45/361 (12%) in RAL arm. In DTG arm failure was not associated to emergence of TAMs.

 

Mark Boyd presented  the 96 weeks results of the SECOND-LINE trial. Predictors of virological failure at week 96 were low adherence, higher baseline gGSS, baseline VL>100.000 copies/mL and african ethnicity. 




   

    The organizers reserve the right to amend the programme.